TABLE 1.
The correlation between JCV T antigen existence and clinicopathological features of breast cancer.
| Parameters | n | JCV T antigen | χ2 | p value | |
|---|---|---|---|---|---|
| - | + | ||||
| N staging | 97 | 4.217 | 0.040 | ||
| - | 36 (57.1%) | 27 (42.9%) | |||
| + | 12 (35.3%) | 22 (64.7%) | |||
| E-cadherin expression | 61 | 7.044 | 0.008 | ||
| - | 10 (35.7%) | 18 (64.3%) | |||
| + | 23 (69.7%) | 10 (30.3%) | |||
| ER expression | 100 | 5.762 | 0.016 | ||
| - | 15 (75.0%) | 5 (25.0%) | |||
| + | 36 (45.0%) | 44 (55.0%) | |||
| PR expression | 100 | 6.275 | 0.012 | ||
| - | 17 (73.9%) | 6 (26.1%) | |||
| + | 34 (44.2%) | 43 (55.8%) | |||
| TNBC | 101 | 4.697 | 0.030 | ||
| - | 42 (47.2%) | 47 (52.8%) | |||
| + | 9 (81.8%) | 2 (18.2%) | |||
ER, estrogen receptor; PR, progesterone receptor; TNBC, triple-negative breast cancer.